Rising Biosciences (Rising Biosciences) Growth Rank : 0 (As of Jun. 18, 2024)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Growth Rank?

Rising Biosciences has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Rising Biosciences Growth Rank Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Growth Rank

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.